Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 213

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Baricitinib for COVID-19: a suitable treatment?

Open access
Favalli, Ennio G, Biggioggero, Martina, Maioli, Gabriella, Caporali, Roberto · 2020 · The Lancet Infectious Diseases

Abstract

www.thelancet.com/infection Published online April 3, 2020 https://doi.org/10.1016/S1473-3099(20)30262-0 1 incidence of which might be expected to be higher in immunocompromised patients given JAK inhibitors. In conclusion, we believe that, beyond the intriguing opportunity to directly block the penetration of SARSCoV-2 into the cell, the use of baricitinib in susceptible patients with ongoing pneumonia associated with COVID-19 should be considered with extreme caution.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s1473-3099(20)30262-0

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 213

Metadata

Authors
Favalli, E. G., Biggioggero, M., Maioli, G., & Caporali, R.
Venue
The Lancet Infectious Diseases
Publisher
Elsevier BV
Published
2020-09
Volume
20
Issue
9
Pages
1012-1013
ISSN
1473-3099 (ISSN-L)
OpenAlex
W3015018920
Cited by
213
References
1
FWCI
5.95
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Baricitinib for COVID-19: a suitable treatment? https://app.cochat.ai/papers/10.1016/s1473-3099(20)30262-0
The paper
Favalli, E. G., Biggioggero, M., Maioli, G., & Caporali, R. (2020). Baricitinib for COVID-19: a suitable treatment? The Lancet Infectious Diseases. https://doi.org/10.1016/s1473-3099(20)30262-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.